Autopsy report · NCT05177718

Natalizumab and Chronic Inflammation

“Sponsor declined further support”

The sponsor’s own words in the registry.

Life of this trial

• Registered 9 months before it started.
• Ran for about 7 months before it stopped.
• 1 participant enrolled.
• Results were posted on the registry 1 year after it ended.

Vital statistics

Status

Terminated

Phase

Phase 4

Sponsor

Vanderbilt University Medical Center

Sponsor type

University, hospital or other

Conditions

Multiple Sclerosis

Interventions

Natalizumab 300 MG in 15 ML Injection

Participants

1

Sites

1

Countries

United States

Trials that died the same way

• 18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma
  “loss of sponsor support” (81% match in meaning)
• Vasculaire Leg Compression Device for the Treatment of Restless Legs Syndrome - A Prospective Clinical Study
  “sponsor withdrew support” (80% match in meaning)
• Yttrium-90 Radioembolization + Nivolumab for Liver + Extra-hepatic Metastases From Colorectal Cancer
  “Sponsor chose not to continue” (77% match in meaning)
• Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids
  “Sponsor terminated financial support” (77% match in meaning)
• Pharmacokinetics and Pharmacodynamics of Edoxaban Before and After Bariatric Surgery
  “No support form the sponsor” (76% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.